Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Allison Morgan

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Neuromuscular Disorders : NMD|December 11, 2013
Pharmacokinetics and safety of single doses of drisapersen in non-ambulant subjects with Duchenne muscular dystrophy: results of a double-blind randomized clinical trialKevin M Flanigan, Thomas Voit, Xiomara Q Rosales, et al.
Plos One|April 1, 2026
Facility-level integration of hypertension and diabetes services with HIV treatment in sub-Saharan Africa: Observational evidence from Malawi, South Africa, and ZambiaLinda Sande, Mariet Benade, Timothy Tchereni, et al.
Medrxiv : the Preprint Server for Health Sciences|August 6, 2025
Client preferences for service delivery during the early treatment period in South Africa and Zambia: Mixed-method findings from a discrete choice experiment and concurrent focus group discussionsAllison Morgan, Linda Sande, Mhairi Maskew, et al.
Scientific Reports|August 5, 2024
Personalizing driver safety interfaces via driver cognitive factors inferenceEmily S Sumner, Jonathan DeCastro, Jean Costa, et al.
The Lancet. Neurology|September 12, 2014
Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 studyThomas Voit, Haluk Topaloglu, Volker Straub, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Neuromuscular Disorders : NMD|December 11, 2013
Pharmacokinetics and safety of single doses of drisapersen in non-ambulant subjects with Duchenne muscular dystrophy: results of a double-blind randomized clinical trialKevin M Flanigan, Thomas Voit, Xiomara Q Rosales, et al.
Plos One|April 1, 2026
Facility-level integration of hypertension and diabetes services with HIV treatment in sub-Saharan Africa: Observational evidence from Malawi, South Africa, and ZambiaLinda Sande, Mariet Benade, Timothy Tchereni, et al.
Medrxiv : the Preprint Server for Health Sciences|August 6, 2025
Client preferences for service delivery during the early treatment period in South Africa and Zambia: Mixed-method findings from a discrete choice experiment and concurrent focus group discussionsAllison Morgan, Linda Sande, Mhairi Maskew, et al.
Scientific Reports|August 5, 2024
Personalizing driver safety interfaces via driver cognitive factors inferenceEmily S Sumner, Jonathan DeCastro, Jean Costa, et al.
The Lancet. Neurology|September 12, 2014
Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 studyThomas Voit, Haluk Topaloglu, Volker Straub, et al.
Pageof 3